AstraZeneca (AZ; NASDAQ: AZN), a UK-based pharmaceutical and biopharmaceutical company, has this week announced 3-year results from a Phase III clinical trial of its anti-PD-L1 therapy Imfinzi (durvalumab) in combination with chemotherapy for the treatment of advanced biliary tract cancer (BTC). The trial, after a median follow-up of 41.3 months, indicated that the combination therapy reduced the risk of death by 26% compared to chemotherapy alone, which translates to an increase in overall survival (OS) from 11.3 months to 12.9 months.
Furthermore, the OS rate at the 36-month mark was recorded at 14.6%, which is more than double the 6.9% observed in the control group. The study did not report any new safety signals associated with the treatment.
Imfinzi has already received regulatory approvals for a range of indications, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), hepatocellular carcinoma (HCC), and biliary tract cancer (BTC). – Flcube.com
